Logo image of LABS.CA

MEDIPHARM LABS CORP (LABS.CA) Stock Overview

TSX:LABS - CA58504D1006 - Common Stock

0.08 CAD
+0.01 (+6.67%)
Last: 8/29/2025, 7:00:00 PM

LABS.CA Key Statistics, Chart & Performance

Key Statistics
52 Week High0.12
52 Week Low0.06
Market Cap33.66M
Shares420.76M
Float388.32M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.03
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO02-09 2018-02-09
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


LABS.CA short term performance overview.The bars show the price performance of LABS.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10

LABS.CA long term performance overview.The bars show the price performance of LABS.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10

The current stock price of LABS.CA is 0.08 CAD. In the past month the price increased by 14.29%. In the past year, price increased by 14.29%.

MEDIPHARM LABS CORP / LABS Daily stock chart

LABS.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
WEED-DB.CA CANOPY GROWTH CORP N/A 20.59B
BHC.CA BAUSCH HEALTH COS INC 1.95 3.76B
TLRY.CA TILRAY BRANDS INC N/A 2.08B
CRON.CA CRONOS GROUP INC 50.86 1.36B
DHT-UN.CA DRI HEALTHCARE TRUST 6.59 784.17M
WEED.CA CANOPY GROWTH CORP N/A 657.29M
GUD.CA KNIGHT THERAPEUTICS INC N/A 647.73M
TSND.CA TERRASCEND CORP N/A 580.48M
DHT-U.CA DRI HEALTHCARE TRUST 4.7 559.49M
ACB.CA AURORA CANNABIS INC N/A 416.25M
CPH.CA CIPHER PHARMACEUTICALS INC 25.29 404.46M
HITI.CA HIGH TIDE INC N/A 401.13M

About LABS.CA

Company Profile

LABS logo image MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.

Company Info

MEDIPHARM LABS CORP

151 John Street

Barrie ONTARIO L4N 2L1 CA

CEO: Patrick McCutcheon

Employees: 161

LABS Company Website

LABS Investor Relations

Phone: 17057197425

MEDIPHARM LABS CORP / LABS.CA FAQ

What is the stock price of MEDIPHARM LABS CORP today?

The current stock price of LABS.CA is 0.08 CAD. The price increased by 6.67% in the last trading session.


What is the ticker symbol for MEDIPHARM LABS CORP stock?

The exchange symbol of MEDIPHARM LABS CORP is LABS and it is listed on the Toronto Stock Exchange exchange.


On which exchange is LABS.CA stock listed?

LABS.CA stock is listed on the Toronto Stock Exchange exchange.


What is MEDIPHARM LABS CORP worth?

MEDIPHARM LABS CORP (LABS.CA) has a market capitalization of 33.66M CAD. This makes LABS.CA a Nano Cap stock.


How many employees does MEDIPHARM LABS CORP have?

MEDIPHARM LABS CORP (LABS.CA) currently has 161 employees.


What are the support and resistance levels for MEDIPHARM LABS CORP (LABS.CA) stock?

MEDIPHARM LABS CORP (LABS.CA) has a support level at 0.07 and a resistance level at 0.09. Check the full technical report for a detailed analysis of LABS.CA support and resistance levels.


Is MEDIPHARM LABS CORP (LABS.CA) expected to grow?

The Revenue of MEDIPHARM LABS CORP (LABS.CA) is expected to grow by 13.37% in the next year. Check the estimates tab for more information on the LABS.CA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MEDIPHARM LABS CORP (LABS.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MEDIPHARM LABS CORP (LABS.CA) stock pay dividends?

LABS.CA does not pay a dividend.


When does MEDIPHARM LABS CORP (LABS.CA) report earnings?

MEDIPHARM LABS CORP (LABS.CA) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of MEDIPHARM LABS CORP (LABS.CA)?

MEDIPHARM LABS CORP (LABS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).


LABS.CA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to LABS.CA. When comparing the yearly performance of all stocks, LABS.CA turns out to be only a medium performer in the overall market: it outperformed 54.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LABS.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LABS.CA. While LABS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LABS.CA Financial Highlights

Over the last trailing twelve months LABS.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.5% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.56%
ROE -21.74%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%21.86%
EPS 1Y (TTM)22.5%
Revenue 1Y (TTM)17.72%

LABS.CA Forecast & Estimates

For the next year, analysts expect an EPS growth of 61.75% and a revenue growth 13.37% for LABS.CA


Analysts
Analysts42.22
Price TargetN/A
EPS Next Y61.75%
Revenue Next Year13.37%

LABS.CA Ownership

Ownership
Inst OwnersN/A
Ins Owners6.71%
Short Float %N/A
Short RatioN/A